NSAID augmentation in inflammation-elevated TRD has accumulated meaningful evidence — particularly celecoxib added to standard antidepressant treatment in patients with elevated inflammatory markers. The mechanism is COX-2 inhibition with downstream effects on prostaglandin synthesis and neuroinflammation. The clinical use is selective — reserved for patients with documented inflammation, adequate prior anti-inflammatory interventions, and informed consent about the trade-offs of chronic NSAID exposure. The discipline is to use this where evidence supports it without making chronic NSAIDs a routine TRD intervention.
The celecoxib evidence. Multiple trials have shown improved depression response with celecoxib (200mg twice daily) added to standard antidepressant in patients with TRD, particularly those with elevated inflammation. Effect sizes are modest but meaningful. The mechanism is COX-2 inhibition reducing pro-inflammatory prostaglandin synthesis; the effect is amplified in patients whose depression has substantial inflammatory contribution. Celecoxib is preferred over non-selective NSAIDs (ibuprofen, naproxen) due to better GI safety profile, though cardiovascular concerns remain.
The clinical scenarios where NSAID augmentation is reasonable. Documented inflammation-elevated TRD (hs-CRP >3 mg/L) with persistent depression despite optimization of standard treatment and adequate omega-3 augmentation. Patients without strong contraindications to chronic NSAID exposure (no active GI disease, no significant cardiovascular contraindications, no significant renal impairment). Informed consent about the off-label use, modest expected benefit, and chronic NSAID exposure risks. The clinical reasoning supports time-limited trials (8–12 weeks) with reassessment, not indefinite augmentation.
The chronic NSAID exposure considerations are substantial. GI bleeding risk increases with chronic use, with cumulative risk particularly relevant in older patients. Cardiovascular risk — COX-2 inhibitors have specific concerns about cardiovascular events; the rofecoxib withdrawal experience shapes current caution. Renal effects with chronic exposure. Drug interactions. Each of these reduces the threshold for reconsidering chronic NSAID augmentation; the trial should produce clear benefit to justify continuation.
The realistic clinical place. NSAID augmentation is not first-line; it is augmentation after adequate first-line treatment in selected inflammation-elevated TRD. The expected benefit is modest. The risks accumulate with chronic exposure. Time-limited trials with reassessment are the appropriate format. For patients who respond clearly, the long-term decision involves balancing continued benefit against accumulating exposure risk; some clinicians reduce to lower doses or alternate-day dosing for chronic maintenance. The discipline is to use this intervention where evidence supports it, monitor the risk-benefit thoughtfully across the trial, and reserve chronic use for patients with clear sustained benefit and acceptable risk profile.